Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk

Metabolism: Clinical and Experimental

Volumn 57, Issue 2, 2008, Pages 207-214

  Onat, Altan ^a,b   Can, Günay ^b   Hergenç, Gülay ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC BALANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; METABOLIC DISEASES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 38049024079     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.09.002     Document Type: Article

References (31)

1. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979 [Erratum, N Engl J Med 1997;337:356]
2. Koenig W., Sund M., Fröhlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsburg cohort study, 1984 to 1992. Circulation 99 (1999) 237-242
3. Pirro M., Bergeron J., Dagenais G.R., et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 161 (2001) 2474-2480
4. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease: prospective study and updated meta-analysis. N Engl J Med 350 (2004) 1387-1397
5. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
6. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
7. Doggen C.J., Berckmans R.J., Sturk A., Manger Cats V., and Rosendaal F.R. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med 248 (2000) 406-414
8. Than T.S., Sattar N., Williams K., Gonzales-Villapando C., Lean M.E.J., and Haffner S.M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25 (2002) 2016-2021
9. Laaksonen D.E., Niskanen L., Nyyssonen K., et al. C-reactive protein and the development of metabolic syndrome and diabetes in middle-aged men. Diabetologia 47 (2004) 1403-1410
10. Engström G., Janzon L., Berglund G., et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 22 (2002) 2054-2058
11. Niskanen L., Laaksonen D.E., Nyyssonen K., et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 44 (2004) 859-865
12. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2948-2951
13. Cifkova R., Frohlich J., Skodova Z., et al. C-reactive protein and the risk of developing the metabolic syndrome. A population study. Eur Heart J Suppl 26 (2005) 445
14. Timpson N.J., Lawler D.A., Harbord R.M., et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 366 (2005) 1954-1959
15. Faraj M., Messier L., Bastard J.P., et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 49 (2006) 1637-1646
16. Onat A., Ceyhan K., Başar Ö., Erer B., Toprak S., and Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 165 (2002) 285-292
17. Onat A., Can G., Hergenç G., Yazi{dotless}ci{dotless} M., Karabulut A., and Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension, diabetes, independent of markers of central obesity and inflammation. Int J Obes 31 (2007) 1119-1125
18. Onat A., Özhan H., Esen A.M., et al. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit. Atherosclerosis 193 (2007) 380-389
19. Grundy S.M. Inflammation, hypertension, and the metabolic syndrome. JAMA 290 (2003) 3000-3002
20. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 156 (2001) 1-10
21. Genuth S., Alberti K.G., Bennett P., et al. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 (2003) 3160-3167
22. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 285 (2001) 2486-2497
23. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
24. Onat A., Hergenç G., Türkmen S., Yazi{dotless}ci{dotless} M., Sari{dotless} İ., and Can G. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism 55 (2006) 445-452
25. Onat A., Uyarel H., Hergenç G., Karabulut A., Albayrak S., and Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191 (2007) 182-190
26. Mather K.J., Hunt A.E., Steinberg H.O., et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86 (2001) 5457-5464
27. Rose G., Blackburn H., Gillum R.F., and Prineas R.J. Cardiovascular survey methods. 2nd ed. (1982), WHO, Geneva 124-127
28. Fröhlich M., Sund M., Löwel H., Imhof A., Hoffmeister A., and Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men: results from a representative sample of the general population (MONICA Augsburg Survey 1994/1995). Eur Heart J 24 (2003) 1365-1372
29. Paffen E., and deMaat M.P.M. C-reactive protein in atherosclerosis: a causal factor?. Cardiovasc Res 71 (2006) 30-39
30. Onat A., Sansoy V., Yi{dotless}ldi{dotless}ri{dotless}m B., Keleş İ., Uysal Ö., and Hergenç G. C-reactive protein and coronary heart disease in western Turkey. Am J Cardiol 88 (2001) 600-607
31. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for health care professionals. From the Centers of Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511